Program
Evarucabgene Autoleucel
Also written as “NXC-201” and “NXC-201 CAR-T”.
Its studies are mostly in Amyloidosis · Immunoglobulin Light-chain Amyloidosis, led by Nexcella.
Furthest: phase 3, since Jul 12, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nexcella | 22 open or running | phase 3since Jul 12, 2026 | Oct 14, 2023 | Dec 2026phase 2 · NCT06097832 |
Also a collaborator on its studies: Immix Biopharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 14, 2023First study: phase 2 study in AmyloidosisFirst studyNCT06097832 · 45 enrolled · United States
- Jul 12, 2026Phase 3 study in AmyloidosisPhase 3 reachedNCT07709715 · 260 planned
Ahead
- Dec 2026Primary completion: phase 2 study in AmyloidosisNCT06097832
- Dec 2028Primary completion: phase 3 study in AmyloidosisNCT07709715
TargetBeta
TNFRSF17 →read by rule
“A preparation of autologous T-lymphocytes that have been transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) specific for the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) ”NCIt, by rule
Other programs on TNFRSF17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| belantamab mafodotinrule | GlaxoSmithKline | phase 3 | 25 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| anitocabtagene autoleucelrule | Gilead Sciences | phase 3 | 6 |
| equecabtagene autoleucelrule | nanjing-iaso-biotechnology-co-ltd | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrule | cartesian-therapeutics | phase 2 | 6 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07709715Amyloidosis | 3 | Not yet recruiting | Dec 2028 | 260 |
| NCT06097832Amyloidosis · United States | 2 | Active, not recruiting | Dec 2026 | 45 |
How it is read
Names in the registry
- “NXC-201”, 1 entry
- “NXC-201 CAR-T”, 1 entry
Conditions, from the studies’ own filings
- Amyloidosis, 1 study
- Immunoglobulin Light-chain Amyloidosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.